top of page

  1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261

  2. Potkin S, Bera R, Zubek D, Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry. 2013;13(1):1-11. doi:10.1186/1471-244X-13-261

  3. Wang D, Schneider-Thoma J, Siafis S, et al. Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: systematic review and network meta-analysis. European Neuropsychopharmacology. 2024;83:11-18. doi:10.1016/j.euroneuro.2024.03.003

  4. Johnson D a. W. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S7-S12. doi:10.1192/bjp.195.52.s7

  5. Heres S. Long-acting injectable antipsychotics: an underutilized treatment option: (commentary). J Clin Psychiatry. 2014;75(11):1263-1265. doi:10.4088/JCP.14com09541

  6. Kane JM, Schooler NR, Marcy P, et al. Effect of Long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217-1224. doi:10.1001/jamapsychiatry.2020.2076

  7. Zagorski N. Too little, too late: LAIs remain underused. PN. 2023;58(11). doi:10.1176/appi.pn.2023.11.10.50

  8. Corigliano V, Comparelli A, Mancinelli I, et al. Long-acting injectable second-generation antipsychotics improve negative symptoms and suicidal ideation in recent diagnosed schizophrenia patients: a 1-year follow-up pilot study. Schizophr Res Treatment. 2018;2018:4834135. doi:10.1155/2018/4834135

  9. Citrome L. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Review of Neurotherapeutics. 2017;17(10):1029-1043. doi:10.1080/14737175.2017.1371014

  10. Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171-1180. doi:10.2147/PPA.S53795

  11.  Boyer L, Falissard B, Nuss P, et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol Psychiatry. 2023;28(9):3709-3716. doi:10.1038/s41380-023-02175-z

  12. Fannon D, Chitnis X, Doku V, et al. Features of structural brain abnormality detected in first-episode psychosis. AJP. 2000;157(11):1829-1834. doi:10.1176/appi.ajp.157.11.1829

  13. Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. AJP. 2013;170(6):609-615. doi:10.1176/appi.ajp.2013.12050674

  14. Bartzokis G, Lu PH, Raven EP, et al. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophrenia Research. 2012;140(1-3):122-128. doi:10.1016/j.schres.2012.06.036

  15. Malla AK, Bodnar M, Joober R, Lepage M. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. Schizophr Res. 2011;125(1):13-20. doi:10.1016/j.schres.2010.09.021

  16. Hamina A, Taipale H, Lieslehto J, et al. Comparative effectiveness of antipsychotics in patients with schizophrenia spectrum disorder. JAMA Network Open. 2024;7(10):e2438358. doi:10.1001/jamanetworkopen.2024.38358

  17. VandenBerg AM. An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use. Ment Health Clin. 2022;12(5):270-281. doi:10.9740/mhc.2022.10.270

  18. Hu A. A practical review of long-acting injectable antipsychotics. US Pharmacist. Accessed December 1, 2024. https://www.uspharmacist.com/article/a-practical-review-of-longacting-injectable-antipsychotics

  19. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67(suppl 5):18488.

  20. Blackwood C, Sanga P, Nuamah I, et al. Patients’ preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the Patient-Reported Medication Preference Questionnaire. Patient Prefer Adherence. 2020;14:1093-1102. doi:10.2147/PPA.S251812

  21. Højlund M, Correll CU. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opinion on Pharmacotherapy. 2023;24(13):1463-1489. doi:10.1080/14656566.2023.2228686

  22. Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39. doi:10.1007/s40263-020-00779-5

  23. Teva presents new phase 3 efficacy, safety and tolerability data from SOLARIS trial evaluating TEV-’749 (olanzapine) as a once-monthly subcutaneous long-acting injectable for adult patients diagnosed with schizophrenia. Financial Post. Accessed November 24, 2024. https://financialpost.com/globe-newswire/teva-presents-new-phase-3-efficacy-safety-and-tolerability-data-from-solaris-trial-evaluating-tev-749-olanzapine-as-a-once-monthly-subcutaneous-long-acting-injectable-for-adult-patients-diagnosed

  24. Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD. Perceived burdens and educational needs of caregivers of people with schizophrenia: results of a national survey study. Patient Prefer Adherence. 2022;16:159-168. doi:10.2147/PPA.S326290

  25. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361-1367. doi:10.1007/s11606-012-2077-6

  26. Barbui C, Bertolini F, Bartoli F, et al. Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study - PMC. Ther Adv Psychopharmacol. 2020;10:2045125320978102.

  27. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275-282. doi:10.1097/YIC.0b013e3280c28424

  28. Lindenmayer JP, Glick ID, Talreja H, Underriner M. Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of schizophrenia. J Clin Psychopharmacol. 2020;40(4):346-349. doi:10.1097/JCP.0000000000001225

  29. Caroli, Raymondet P, Izard, Plas, Gall B, Delgado. Opinions of French patients with schizophrenia regarding injectable medication. PPA. Published online March 2011:165. doi:10.2147/PPA.S15337

  30. Keenan A, Lin D, Shepherd J, Bailey H, Benson C, Meakin S. Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey. BMC Psychiatry. 2022;22(1):187. doi:10.1186/s12888-022-03846-x

  31. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. PS. 2007;58(9):1187-1192. doi:10.1176/ps.2007.58.9.1187

  32. Byerly MJ, Thompson A, Carmody T, et al. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. PS. 2007;58(6):844-847. doi:10.1176/ps.2007.58.6.844

  33. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998;172(33):53-59.

  34. Mucci A, Kawohl W, Maria C, Wooller A. Treating schizophrenia: open conversations and stronger relationships through psychoeducation and shared decision-making. Front Psychiatry. 2020;11. doi:10.3389/fpsyt.2020.00761

© 2025 CMEology

bottom of page